Momentum Bioscience

Momentum Bioscience (MB) was founded as a shell in 2005 by seasoned diagnostics executive, Dr Bill Mullen, beginning operations in 2008.

MB is developing tests for the early detection of blood-borne microbial infections which could potentially lead to sepsis. There is an urgent need to develop rapid tests to rule out bacteria or fungi in blood cultures, thereby reducing the time to verify a negative result and potentially enabling the 90% of patients with negative results to be taken off antibiotics, thus reducing both drug costs and the risk of developing anti-microbial resistance (AMR). The Company’s Magnitor Rule-Out test, which is based on its ETGA (Enzyme Template Generation and Amplification) technology, gives results four days earlier than current tests, facilitating improved antibiotic stewardship and outcomes.

Visit website